Company intelligence / Profile preview

NovoHelix

Ownership: Private
Development stage: Preclinical

Overview

NovoHelix develops advanced genome engineering tools and custom animal/cell models to support biomedical research. Their technologies enable precise genetic modifications in rodents and livestock as well as stem cell-based disease modeling. They do not develop therapeutics themselves but provide critical infrastructure for preclinical discovery.

Therapeutic areas: Other
Modalities: Gene editing technologyCell therapyGenome engineering platformsStem cell products
Industry: Non-Drug Biotech

Partnerships

Trophogen Inc.

Beyond the preview

Go deeper on NovoHelix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoHelix.

Explore the full profile